Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Longer activity bouts link to lower future dementia and mental health risks

23

Jul 2026

Longer activity bouts link to lower future dementia and mental health risks

A UK Biobank analysis of 66,483 adults found that longer daily moderate-to-vigorous activity bouts and less fragmented activity were associated with lower subsequent risks of inpatient diagnoses of dementia, depression, and anxiety, independent of total activity time. In neuroimaging data from 13,108 participants, these activity patterns were also associated with more favorable brain measures, although the observational analyses cannot establish cause and effect.

Evidence shows artificial sweeteners cannot be judged as a single group

23

Jul 2026

Evidence shows artificial sweeteners cannot be judged as a single group

This narrative review found that non-nutritive artificial sweeteners have compound-specific and context-dependent associations with gut microbiota, metabolism, and health-related outcomes. Evidence does not support treating all sweeteners as uniformly harmful or safe, with human findings often limited or inconsistent.

Higher neuroticism may curb strenuous exercise, genetic analysis suggests

23

Jul 2026

Higher neuroticism may curb strenuous exercise, genetic analysis suggests

Researchers used a UK survey and genetic data to examine whether higher neuroticism is associated with lower exercise engagement. Under the study’s Mendelian randomization assumptions, higher neuroticism was estimated to reduce participation in moderate and vigorous physical activity, while conscientiousness may lessen this effect.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.